The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. by Peiqi Yin (6533747)

<b>Warming alters plankton body-size distributions in a large field experiment</b> by Dania Albini (20288463)

“…We found a nonlinear decrease in the overall mean body size of zooplankton with warming, with a 57% reduction at +8°C. …”

<b>The loss of insulin-positive cell clusters precedes the decrease of islet frequency and beta cell area in type 1 diabetes</b> by Denise M. Drotar (21679539)

“…Moreover, changes in endocrine composition also occurred in mAAb+ donors, including a significant decrease in the INS+ islet fraction. …”

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Average self-reported physical health ratings before or during the COVID-19 pandemic among individuals who engaged during the pandemic in more than 3 (A), 4 (B), or 5 (C) positive... by Elie Mulhem (22537863)

Subjects:

Bacterial abundance in L2 larvae collected from larval flasks inoculated with decreasing quantities of glycerol stock (bacteria source). by Margaret V. Becker (21387776)

Maps of median projected λ_<i>S</i> (a) and <i>R</i>₀ (b) across 1st-level sub-national administrative regions in selected African countries. by Keith Fraser (1868587)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Polylactic Acid/Polybutylene Adipate Terephthalate-Carbon Nanotube Nanobiocomposites with a Segregated Toughening Morphology Yielding Large Ductility for Biocompatible Materials by Utsab Ayan (18552401)

Maps of median projected λ_<i>S</i> (a) and <i>R</i>₀ (b) across 1st-level sub-national administrative regions in selected South American countries. by Keith Fraser (1868587)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 ^a indicates ≥1.50 SD (20.2) from the mean (36.... by Luke R. Cavanah (19022435)